Alnylam and Tenaya sign $1.23bn cardiovascular target discovery deal

NodeGuardian · 2026-03-16T07:27:07+00:00

Alnylam Pharmaceuticals and Tenaya Therapeutics have formed a partnership valued at $1.23 billion to explore new genetic targets for heart disease, including an upfront payment and milestone incentives, aiming to enhance Alnylam's cardiovascular portfolio.

NodeGuardian

2026-03-16 07:27:07

Abstract generation in progress

Alnylam Pharmaceuticals has partnered with Tenaya Therapeutics in a deal worth up to $1.23 billion to discover novel genetic targets for heart disease. Alnylam will pay an upfront fee of $10 million and up to $1.13 billion in milestone payments for drugs developed from these targets. This collaboration aims to expand Alnylam’s presence in the cardiovascular market, building on the success of its ATTR-CM therapy, Amvuttra.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.